Home Tags CSL Behring

Tag: CSL Behring

CSL completes acquisition of novel gene therapy for haemophilia B

CSL Limited has wrapped up the acquisition of uniQure’s etranacogene dezaparvovec, a novel gene therapy for the treatment of haemophilia B. Under the agreement, CSL...

TGA approves domestic manufacture of AstraZeneca vaccine

CSL has been given the nod by the Therapeutic Goods Administration (TGA) to commence the manufacture of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S) in Australia. TGA’s...

Bosch Australia’s Manufacturing Solutions business unit awarded plasma process automation contract by CSL Behring

Media Release Bosch Australia’s Manufacturing Solutions division (BAMS) has been awarded a contract to create a high-tech automatic materials handling line for CSL Behring (Australia),...

CSL Behring buys US biotech company Calimmune

CSL Behring, the major operating arm of the CSL Group, has agreed to acquire US Biotechnology company Calimmune, Inc. for an upfront payment of...

CSL to buy majority stake in a leading Chinese plasma fractionator

Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...

2016 Victorian Manufacturing Hall of Fame Gala Dinner announces award recipients

The Australian Labor Government has recognised exemplary companies and individuals in the Victorian manufacturing industry at the 2016 Manufacturing Hall of Fame gala Dinner. Broadmeadows-based...

Industrial action continues at CSL Behring’s manufacturing plant  

AMWU members at CSL Behring, who make vital blood plasma products and maintain factory equipment, staged a 4-hour work stoppage last Friday in response...
Advertisement